Genomic analysis of Smoothened inhibitor resistance in basal cell carcinoma

Smoothened (SMO) inhibitors are under clinical investigation for the treatment of several cancers. Vismodegib is approved for the treatment of locally advanced and metastatic basal cell carcinoma (BCC). Most BCC patients experience significant clinical benefit on vismodegib, however, some develop re...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancer Cell
Asıl Yazarlar: Sharpe, Hayley J., Pau, Gregoire, Dijkgraaf, Gerrit J., Basset-Seguin, Nicole, Modrusan, Zora, Januario, Thomas, Tsui, Vickie, Durham, Alison B., Dlugosz, Andrzej A., Haverty, Peter M., Bourgon, Richard, Tang, Jean Y., Sarin, Kavita Y., Dirix, Luc, Fisher, David C., Rudin, Charles M., Sofen, Howard, Migden, Michael R., Yauch, Robert L., de Sauvage, Frederic J.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2015
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5675004/
https://ncbi.nlm.nih.gov/pubmed/25759019
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccell.2015.02.001
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller